Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
Patent 6316457 Issued on November 13, 2001. Estimated Expiration Date: February 10, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/263.34, Chalcogen bonded directly to the 2-and 6- positions of the purine ring system (e.g., theophylline, etc.)544/272Nitrogen attached directly or indirectly to the purine ring system by nonionc bonding
Disclosed are nitrosated and/or nitrosylated phosphodiesterase inhibitors having the formula NOn -PDE inhibitor where n is 1 or 2. The invention also provides compositions comprising such compounds in a pharmaceutically acceptable carrier. The invention also provides a composition comprising a therapeutically effective amount of an phosphodiesterase inhibitor (PDE inhibitor), which can optionally be substituted with at least one NO or NO2 moiety, and one to ten fold molar excess of a compound that donates, transfers or releases nitrogen monoxide as a charged species, i. e., nitrosonium (NO+) or nitroxyl (NO-), or as the neutral species, nitric oxide (NO⋅) or which stimulates endogenous EDRF production. The invention also provides compositions comprising such compounds in a pharmaceutically acceptable carrier. The invention also provides methods for treating sexual dysfunctions in males and females.
Other References
Takase et al., Chem. Abstract 119:203427, 1993.
Lugnier et al., Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilation, Eur. Heart J., 14 Suppl. I, pp. 141-148 (PubMed Abstract), Nov. 1993.
Meskini et al., Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation, Biochem. Pharmacol., 47(5), pp. 781-788 (PubMed Abstract), Mar. 1994.
Zorgniotti et al, Int. J. Impotence Res., 6:33-36 (1994)
Boolell et al, Int. J. Impotence Res., 8:47-52 (1996)
Krane et al, New England Journal of Medicine, 321(24):1648-1659 (1989)
Trigo-Rocha et al, Neurourol. Urodyn., 13(1):71-80 (1994)
Sparwasser et al, J. Urol., 152:6, Pt. 1, pp. 2159-2163 (1994)
Chemical Abstracts, 120(1):612, Abstract 5451d (1994)
Chen et al, BJU International, 83:269-273 (1999)
Mathers et al, European Urology, 35(suppl 2):67 (abstract 266) (1999)
Park et al, Biochem. Biophys. Res. Commun., 249(3):612-617 (1998)
Terrett et al, Bioorg. Med. Chem. Lett., 6(15):1819-1824 (1996)
Boolell et al, British Journal of Urology, 78(2):257-261 (1996)
Martel et al, Drugs of the Future, 22(2) :138-143 (1997)
February 10, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
